Abstract

PCN100 - Cost-Effectiveness Model of Pertuzumab in Combination with Trastuzumab and Docetaxel Compared with Trastuzumab in Combination with Docetaxel for the 1st Line Treatment of HER2+ Metastatic Breast Cancer in Colombia

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call